Home » Posts tagged with » Daniel O’Day
Gilead Sciences bags Descovy FDA approval for prevention of HIV infection

Gilead Sciences bags Descovy FDA approval for prevention of HIV infection

Descovy FDA approval : Gilead Sciences’ Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) has been approved by the US Food and Drug Administration for HIV Pre-Exposure Prophylaxis (PrEP) or in other words prevention of HIV infection.. PrEP is defined as an HIV prevention method in which medicine is taken everyday before […]

Gilead Sciences names Lilly senior VP Christi L. Shaw as Kite CEO

US biopharma company Gilead Sciences has named Christi L. Shaw as the new chief executive officer of its subsidiary Kite, a California-based cell therapy company, which the former acquired for about $11.9 billion in 2017. Christi L. Shaw, who will also become a member of the senior leadership team of Gilead Sciences, is said to […]

Continue reading …